20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Prelude Therapeutics Inc (PRLD) operates in the BIOTECHNOLOGY industry and is headquartered in Wilmington, United States with about 79 employees. Its market capitalization is roughly $309 million. In the fiscal year ended 2025-12-31, PRLD reported $12M in revenue and ($99M) in net income.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Interactive charts & full statements → Open the PRLD valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $23M | $12M | $7M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $22M | $10M | $7M | ($1M) | ($3M) | ($2M) | ($1M) | $0M | $0M |
| Gross Margin % | 95.7% | 85.9% | 100.0% | — | — | — | — | — | — |
| Operating Income (EBIT) | ($66M) | ($105M) | ($140M) | ($132M) | ($124M) | ($114M) | ($59M) | ($28M) | ($15M) |
| Operating Margin % | -287.0% | -861.3% | -1995.9% | — | — | — | — | — | — |
| Net Income | ($60M) | ($99M) | ($127M) | ($122M) | ($107M) | ($111M) | ($57M) | ($28M) | ($15M) |
| Net Margin % | -260.9% | -819.6% | -1816.8% | — | — | — | — | — | — |
| EBITDA | ($59M) | ($98M) | ($125M) | ($121M) | ($122M) | ($113M) | ($58M) | ($28M) | ($15M) |
| Earnings Per Share (EPS) | $-0.79 | $-1.29 | $-1.68 | $-2.02 | $-2.27 | $-2.33 | $-1.30 | $-0.85 | $-9.31 |
| Shares Outstanding (M) | 98M | 77M | 76M | 60M | 47M | 48M | 44M | — | 2M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $6M | $5M | $6M | $6M | $0M | $0M | $4M | $3M |
| Gross Profit | $6M | $4M | $6M | $6M | $0M | $0M | $4M | $3M |
| Gross Margin % | 100.0% | 91.5% | 100.0% | 100.0% | — | — | 100.0% | 100.0% |
| Operating Income (EBIT) | ($15M) | ($14M) | ($17M) | ($20M) | ($32M) | ($35M) | ($34M) | ($34M) |
| Operating Margin % | -270.9% | -309.5% | -307.6% | -314.1% | — | — | -845.8% | -1145.9% |
| Net Income | ($14M) | ($10M) | ($16M) | ($20M) | ($31M) | ($32M) | ($29M) | ($32M) |
| Net Margin % | -244.1% | -226.8% | -291.8% | -303.5% | — | — | -718.3% | -1075.7% |
| EBITDA | ($14M) | ($10M) | ($16M) | ($19M) | ($31M) | ($32M) | ($28M) | ($32M) |
| Earnings Per Share (EPS) | $-0.14 | $-0.13 | $-0.26 | $-0.26 | $-0.41 | $-0.42 | $-0.38 | $-0.43 |
| Shares Outstanding (M) | 98M | 83M | 63M | 76M | 76M | 76M | 76M | 76M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($34M) | ($56M) | ($103M) | ($107M) | ($84M) | ($84M) | ($46M) | ($26M) | ($13M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $4M | $3M | $2M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($34M) | ($56M) | ($104M) | ($111M) | ($87M) | ($86M) | ($47M) | ($26M) | ($13M) |
| FCF Margin % | -147.8% | -464.3% | -1480.7% | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($16M) | ($22M) | $23M | ($19M) | ($26M) | ($34M) | ($21M) | ($27M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($16M) | ($22M) | $23M | ($19M) | ($26M) | ($34M) | ($21M) | ($27M) |
| FCF Margin % | -273.0% | -473.5% | 409.9% | -294.1% | — | — | -519.9% | -912.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $189M | $141M | $176M | $278M | $220M | $305M | $224M | $22M | $16M |
| Cash & Cash Equivalents | $26M | $35M | $12M | $25M | $31M | $32M | $218M | $19M | $16M |
| Total Liabilities | $56M | $73M | $44M | $41M | $25M | $19M | $11M | $71M | $39M |
| Total Debt (Short + Long-Term) | $3M | $3M | $3M | $1M | $2M | $2M | $0M | $0M | $0M |
| Total Shareholders' Equity | $134M | $69M | $131M | $237M | $195M | $286M | $212M | ($49M) | ($23M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRLD viewer.
About TickerBase · Data methodology & sources · Privacy · Terms